RxDoctor Payments Data

George Panas, MD

Cardiology · Chestertown, MDNPI 1508800095

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 88.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $305 and has fallen 66.2% since, to $103 in 2025.

$1,146in general payments, 2019–2025

Across 25 payments — averaging $45.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Pfizer$61
  • Johnson & Johnson$24
  • Boehringer Ingelheim$24
  • E.r. Squibb & Sons, L.L.C.$21

What the payments were for

  • Food & beverage$1,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)17$1,016
Pfizer4$61
Johnson & Johnson2$24
Boehringer Ingelheim1$24
E.r. Squibb & Sons, L.L.C.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,146 in reported general payments places this provider in the 70th percentile of 44 cardiology providers in Maryland.

See all cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$373,570
Medicare patients
485
Services billed
2,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$194,197
XareltoRivaroxaban237$174,038
Repatha SureclickEvolocumab81$68,796
Metoprolol Succinate269$3,983
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,744
Losartan Potassium92$1,549
Carvedilol59$564
Metoprolol Tartrate45$556
Ezetimibe11$472
ClopidogrelClopidogrel Bisulfate61$471
Amlodipine Besylate68$468
Furosemide115$439
Rosuvastatin Calcium19$437
Atorvastatin Calcium51$431
Amiodarone Hcl20$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$194,197238 claims
Johnson & JohnsonXarelto$24$174,038237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 cardiology providers in Maryland.

Other cardiology in Chestertown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →